GB00BN4HT335
© PR Newswire
19.11.2025
INDV
LISTED
NASDAQ
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
RICHMOND, Va., Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference:...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
INDV
LISTED
NASDAQ
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
News Preview
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization
Adherence to SUBLOCADE was associated with lower rates of infectious disease compl...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
INDV
LISTED
NASDAQ
Indivior to Participate in Upcoming Investor Events
News Preview
RICHMOND, Va., Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events:
Morgan Stanley 23rd Annual Global Healthcare Conference – New York City, NYJoe Ciaf...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
25.07.2025
INDV
LISTED
NASDAQ
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Autho...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
23.07.2025
INDV
LISTED
NASDAQ
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
News Preview
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare res...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
INDV
LISTED
NASDAQ
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
News Preview
RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
INDV
LISTED
NASDAQ
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
News Preview
RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
INDV
LISTED
NASDAQ
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
News Preview
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
INDV
LISTED
NASDAQ
Indivior Appoints Tony Kingsley to the Board of Directors
News Preview
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., wh...
Themefolio
Profiler
Peergroup
© PR Newswire
19.06.2025
INDV
LISTED
NASDAQ
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
News Preview
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often aff...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
INDV
LISTED
NASDAQ
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
News Preview
SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"...
Themefolio
Profiler
Peergroup
© PR Newswire
27.05.2025
INDV
LISTED
NASDAQ
Indivior Announces Patrick Barry as Chief Commercial Officer
News Preview
Seasoned commercial executive with more than 30 years of pharmaceutical experience
RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operat...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
13.05.2025
INDV
LISTED
NASDAQ
Indivior to Participate in Upcoming Investor Events
News Preview
RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events:
Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Ex...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
INDV
LISTED
NASDAQ
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
News Preview
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates
RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder Durin...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
INDV
LISTED
NASDAQ
Indivior Announces Q1 2025 Financial Results
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
INDV
LISTED
NASDAQ
Indivior Announces Further Changes to Board of Directors
News Preview
RICHMOND, Va., March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon a...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
INDV
LISTED
NASDAQ
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
News Preview
RICHMOND, Va., Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company's AGM in May...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
INDV
LISTED
NASDAQ
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
News Preview
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD)
RICHMOND, Va., Feb. 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
INDV
LISTED
NASDAQ
Indivior Announces FY and Q4 2024 Financial Results
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© PR Newswire
12.02.2025
INDV
LISTED
NASDAQ
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
News Preview
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE® (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
INDV
LISTED
NASDAQ
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
News Preview
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.Presen...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
INDV
LISTED
NASDAQ
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
News Preview
RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior....
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
INDV
LISTED
NASDAQ
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
News Preview
Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe.Publications highlight the importance of overcoming access barriers to long-acting injectable treatments for OUDRICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Preve...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
INDV
LISTED
NASDAQ
Indivior Announces Q3 2024 Financial Results
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
INDV
LISTED
NASDAQ
Indivior Announces Q3 2024 Financial Results
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at www.indivior.com/investorsThe inves...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
INDV
LISTED
NASDAQ
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
News Preview
Conference Call Today at 8:00 AM US Eastern
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
INDV
LISTED
NASDAQ
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
News Preview
Conference Call Today at 8:00 AM US Eastern
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
INDV
LISTED
NASDAQ
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
News Preview
PDUFA date set for February 7, 2025If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which address significant patient and healthcare provider unmet nee...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
INDV
LISTED
NASDAQ
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC (“Indivior” or “the Company”) (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
INDV
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 1, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”).
If you are a shar...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
INDV
LISTED
NASDAQ
INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the “Class Period”). Indivior PLC is a pharmaceutical company.
For more information, submi...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
INDV
LISTED
NASDAQ
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option SLOUGH...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
INDV
LISTED
NASDAQ
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option SLOUGH...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
INDV
LISTED
NASDAQ
Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness
News Preview
BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and address biosecurity threats involving synthetic opioidsRICHMOND, Va., Aug. 26, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the firs...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
INDV
LISTED
NASDAQ
INDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Indivior PLC (“Indivior” or “the Company”) (NASDAQ: INDV) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violat...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
INDV
LISTED
NASDAQ
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
News Preview
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 1, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Clas...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
INDV
LISTED
NASDAQ
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming October 1, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”).
Investors suffering losse...
Themefolio
Profiler
Peergroup
© BusinessWire
11.08.2024
INDV
LISTED
NASDAQ
INDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
News Preview
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Indivior PLC (“Indivior” or “the Company”) (NASDAQ: INDV) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged viola...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
INDV
LISTED
NASDAQ
Indivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action Lawsuit
News Preview
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Indivior PLC (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024. Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
INDV
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Indivior PLC (INDV) Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”). Ind...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
INDV
LISTED
NASDAQ
Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
Repurchases Under Current Program now Expected to be Completed by End of JulyRICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indiv...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
INDV
LISTED
NASDAQ
Indivior Announces Q2 2024 Financial Results
News Preview
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at www.indivior.com/investorsThe investor presentation...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
INDV
LISTED
NASDAQ
Indivior Announces Q2 2024 Financial Results
News Preview
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
INDV
LISTED
NASDAQ
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
INDV
LISTED
NASDAQ
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the...
Themefolio
Profiler
Peergroup
© PR Newswire
18.06.2024
INDV
LISTED
NASDAQ
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Ca
News Preview
Large reductions in the incidence of simulated cardiac arrest caused by potentially lethal doses of fentanyl or carfentanil were observed following a single IN dose of OPVEE compared to a single dose of IN naloxone. Across scenarios of fentanyl or carfentanil overdoses, simultaneous administration of four doses of IN naloxone (4×4 mg) was needed...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2024
INDV
LISTED
NASDAQ
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
News Preview
Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder.INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals.Recent animal...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
